Patient Preferences for Attributes of Tyrosine Kinase Inhibitor Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer

References

• Hanna N , JohnsonD, TeminSet al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol.35(30), 3484–3515 (2017).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.29(4), iv192–iv237 (2018).
   PubMedGoogle Scholar
• Cho JH . Immunotherapy for non-small-cell lung cancer: current status and future obstacles. Immune Netw.17(6), 378–391 (2017).
   PubMed Web of Science ®Google Scholar
• Tan WW , HuqS. Non-small cell lung cancer (NSCLC) clinical presentation. (2019). https://emedicine.medscape.com/article/279960-clinical
   Google Scholar
• Zhang YL , YuanJQ, WangKFet al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget7(48), 78985–78993 (2016).
   PubMedGoogle Scholar
• Lovly C , HornL, PaoW. EGFR in non-small cell lung cancer (NSCLC). My Cancer Genome (2015). https://www.mycancergenome.org/content/disease/lung-cancer/egfr/
   Google Scholar
• Prabhakar CN . Epidermal growth factor receptor in non-small cell lung cancer. Trans. Lung Cancer Res.4(2), 110–118 (2015).
   PubMed Web of Science ®Google Scholar
• Tseng CH , ChiangCJ, TsengJSet al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget8(58), 98384–98393 (2017).
   PubMedGoogle Scholar
• Sakr L , KasymjanovaG, SmallDIet al. Predicting duration of response to EGFR TKI among EGFR-mutant NSCLC patients. J. Clin. Oncol.34(Suppl. 15), Abstr. e20646 (2017).
   Google Scholar
• Zhu QG , ZhangS, DingX, HeB, ZhangH. Driver genes in non-small cell lung cancer: characteristics, detection methods, and targeted therapies. Oncotarget8(34), 57680–57692 (2017).
   PubMedGoogle Scholar
• Sui H , MaN, WangYet al. Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies. J. Immunol. Res. (2018). www.ncbi.nlm.nih.gov/pmc/articles/PMC6109480/
   PubMed Web of Science ®Google Scholar
• Tartarone A , RovielloG, LeroseRet al. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. Future Oncol.15(20), 2423–2433 (2019)
   PubMed Web of Science ®Google Scholar
• Roviello G , ImperatoriM, AietaM, SollittoF, LandriscinaM. Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?J. Thorac. Dis.10(Suppl. 18), S2114–S2118 (2018).
   PubMedGoogle Scholar
• Rosell R , CarcerenyE, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, ThongprasertSet al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Sequist LV , YangJC-H, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.31(27), 3327–3334 (2013).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Gong J , Chehrazi-RaffleA, ReddiS, SalgiaR. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer.6(1), 8 (2018).
   PubMed Web of Science ®Google Scholar
• Sun A , Durocher-AllenLD, EllisPMet al. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Curr. Oncol.26(3), e372–e384 (2019).
   PubMed Web of Science ®Google Scholar
• Aw DC , TanEH, ChinTM, LimHL, LeeHY, SooRA. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia-Pac. J. Clin. Oncol.14(1), 23–31 (2018).
   PubMed Web of Science ®Google Scholar
• Płużański A , PiórekA. Side effects of tyrosine kinase inhibitors – management guidelines. Oncol. Clin. Pract.12(4), 113–118 (2016).
   Google Scholar
• Takeda M , OkamotoI, NakagawaK. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer88(1), 74–79 (2015).
   PubMed Web of Science ®Google Scholar
• Schmidt K , DammK, PrenzlerA, GolponH, WelteT. Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. Eur. J. Cancer Care (Engl.)25(4), 580–591 (2016).
   PubMed Web of Science ®Google Scholar
• Bridges JFP , HauberAB, MarshallDet al. Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health14(4), 403–413 (2011).
   PubMed Web of Science ®Google Scholar
• Johnson FR , LancsarE, MarshallDet al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health16(1), 3–13 (2013).
   PubMed Web of Science ®Google Scholar
• Hauber AB , GonzalezJM, Groothuis-OudshoornCGet al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health19(4), 300–315 (2016).
   PubMed Web of Science ®Google Scholar
• Janssen EM , SegalJB, BridgesJF. A framework for instrument development of a choice experiment: an application to type 2 diabetes. Patient9(5), 465–479 (2016).
   PubMedGoogle Scholar
• Coast J , Al-JanabiH, SuttonEJet al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ.21(6), 730–741 (2012).
   PubMed Web of Science ®Google Scholar
• US FDA . GILOTRIF (afatinib). Highlights of prescribing information. (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2017/201292s012lbl.pdf
   Google Scholar
• US FDA . IRESSA (gefitinib). Highlights of prescribing information. (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf
   Google Scholar
• US FDA . TAGRISSO (osimertinib). Highlights of prescribing information. (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf
   Google Scholar
• US FDA . TARCEVA (erlotinib). Highlights of prescribing information. (2016). www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
   Google Scholar
• Kim ES , HirshV, MokTet al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Khozin S , WeinstockC, BlumenthalGMet al. Osimertinib for the treatment of metastatic EGFR T790M mutation–positive non–small cell lung cancer. Clin. Cancer Res.23(9), 2131–2135 (2017).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . Common terminology criteria for adverse events v4.0 NCI, NIH, DHHS. NIH publication #09–7473 (2009). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
   Google Scholar
• ChoiceMetrics . Ngene 1.2.0 user manual & reference guide (2018). http://www.choice-metrics.com/NgeneManual120.pdf
   Google Scholar
• Janssen E , MarshallD, HauberA, BridgesJ. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?Expert Rev. Pharmacoecon. Outcomes Res.17(6), 531–542 (2017).
   PubMed Web of Science ®Google Scholar
• McFadden D . Conditional logit analysis of qualitative choice behavior. In: Frontiers in Econometrics.ZarembkaP ( Ed.). Academic Press, NY, USA, 105–142 (1974).
   Google Scholar
• Soekhai V , de Bekker-GrobEW, EllisAR, VassCM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics37(2), 201–226 (2019).
   PubMed Web of Science ®Google Scholar
• Lanscar E , LouviereJ. Conducting discrete choice experiments to inform healthcare decision making: a user‘s guide. Pharmacoeconomics26(8), 661–677 (2008).
   PubMed Web of Science ®Google Scholar
• Janssen E , HauberA, BridgesJ. Conducting a discrete-choice experiment study following recommendations for good research practices: an application to eliciting patient preferences for diabetes treatments. Value Health21(1), 59–68 (2018).
   PubMed Web of Science ®Google Scholar
• Bridges JF , MohamedAF, FinnernHW, WoehlA, HauberAB. Patients‘ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer77(1), 224–231 (2012).
   PubMed Web of Science ®Google Scholar
• Muhlbacher AC , BethgeS. Patients‘ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur. J. Health Econ.16(6), 657–670 (2015).
   PubMed Web of Science ®Google Scholar
• O’Donnell J , RobinsonAG, BoothCMet al. Imaging progression-free survival: how much does it matter to patients?J. Clin. Oncol.36(Suppl. 30), Abstr. 99 (2018).
   Web of Science ®Google Scholar
• Minion LE , ColemanRL, AlvarezRD, HerzogTJ. Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol. Oncol.140(2), 193–198 (2016).
   PubMed Web of Science ®Google Scholar
• Kaklamani VG . Clinical implications of the progression-free survival endpoint for treatment of hormone receptor-positive advanced breast cancer. Oncologist21(8), 922–930 (2016).
   PubMed Web of Science ®Google Scholar
• Schmidt K , DammK, VogelAet al. Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. Patient Prefer. Adherence11, 1647–1656 (2017).
   PubMed Web of Science ®Google Scholar
• Tian Y , ZhaoJ, RenP, WangB, ZhaoC. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma. PLoS ONE (2018). www.ncbi.nlm.nih.gov/pmc/articles/PMC6211626/
   Web of Science ®Google Scholar